Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Balance Sheet

v3.22.4
Condensed Consolidated Interim Balance Sheet - USD ($)
$ in Thousands
Dec. 31, 2022
Jun. 30, 2022
Current assets    
Cash and cash equivalents $ 4,874 $ 11,780
Prepaid expenses, deposits and other 1,079 1,478
Clinical trial deposit 3,225  
Total current assets 9,178 13,258
Clinical trial deposit   2,600
Property and equipment, net 739 90
Total assets 9,917 15,948
Current liabilities    
Accounts payable and accrued liabilities 2,691 3,269
Related party payables 548 721
Total current liabilities 3,239 3,990
Milestone payment liability 80 163
Total liabilities 3,319 4,153
Stockholders' equity    
Common stock Authorized 5,500 shares at December 31, 2022 (June 30, 2022 - 5,500), $0.001 par value 1,673 issued at December 31, 2022 (June 30, 2022 - 1,311) 2 1
Additional paid-in capital 140,571 135,575
Accumulated deficit (144,772) (136,356)
Accumulated other comprehensive income 21 21
Total stockholders’ equity 6,598 11,795
Total liabilities and stockholders’ equity 9,917 15,948
Preferred Stock Series A    
Stockholders' equity    
Preferred stock 279 279
Preferred Stock Series C    
Stockholders' equity    
Preferred stock $ 10,497 $ 12,275